FDA Brief

Warning letters Drugs

FDA warning letter to

Art of Beauty Company, Inc.

High riskIssued May 22, 2024Posted Jul 16, 2024Division of Pharmaceutical Quality Operations III

FDA warned Art of Beauty over manufacturing-rule violations in OTC hand sanitizer, including missing component and finished-product testing.

What happened

FDA inspected the drug manufacturing facility at 200 Egbert Road, Bedford, Ohio, from November 27 to December 1, 2023, and reviewed the company's December 21, 2023 response. FDA found violations of current good manufacturing practice (CGMP), the drug manufacturing rules, including a quality unit without key procedures, incoming components not tested for identity or for diethylene glycol/ethylene glycol (DEG/EG) in glycerin, hand sanitizer not tested for objectionable microorganisms or isopropyl alcohol identity and strength, water not microbiologically tested since June 1, 2023, no process validation, and shared equipment with nail polish remover without validated cleaning.

What FDA found

  1. The quality unit lacked adequate oversight and written procedures for investigations, corrective and preventive actions, change controls, recalls, complaints, and equipment maintenance.

    21 CFR 211.22
  2. The company did not test each incoming component lot for identity and did not test high-risk glycerin for diethylene glycol or ethylene glycol contamination.

    21 CFR 211.84(d)(1)
  3. The company did not test hand sanitizer batches for objectionable microorganisms or test finished hand sanitizer for isopropyl alcohol identity and strength before release.

    21 CFR 211.165(b)
  4. The company did not establish written production and process control procedures and had not validated its manufacturing processes for OTC drug products.

    21 CFR 211.100(a)
  5. The company lacked adequate cleaning and maintenance procedures and used the same equipment for nonpharmaceutical nail polish remover and OTC drugs without validating cleaning to prevent cross-contamination.

    21 CFR 211.67(a) and 211.67(b)

What FDA wants

FDA tells the company to correct the violations promptly and respond in writing within 15 working days with comprehensive assessments and remediation plans. It also asks for DEG/EG test results within 30 calendar days for high-risk component retains, or finished-product testing if retains are unavailable, and recommends a qualified CGMP consultant.

Who should pay attention

  • brands and retailers that sell or distribute its OTC hand sanitizers
  • drug manufacturers that share equipment with non-drug products
  • quality teams at companies using glycerin or isopropyl alcohol in OTC drugs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk